1887
  1. Home
  2. Eurosurveillance
  3. Volume 30, Issue 7, 20/Feb/2025
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

Influenza circulates at high levels in Europe since November 2024. Using a test-negative study based on data from French community laboratories between October 2024 and February 2025, we estimated vaccine effectiveness (VE) against PCR-detected influenza infection (44,420/15,052; positive/negative individuals). For all age groups, the overall VE was 42% (95% CI: 37–46%), with 26% (95% CI: 18–34%) against influenza A and 75% (95% CI: 66–82%) against influenza B. Among individuals ≥ 65-year-olds VE was 22% (95% CI: 13–30%) and among 0–64-year-olds, 60% (95% CI: 56–65%).

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2025.30.7.2500074
2025-02-20
2025-02-26
/content/10.2807/1560-7917.ES.2025.30.7.2500074
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/30/7/eurosurv-30-7-3.html?itemId=/content/10.2807/1560-7917.ES.2025.30.7.2500074&mimeType=html&fmt=ahah

References

  1. Robert Koch Instute (RKI). RKI – Aktueller Wochenbericht – GrippeWeb-Wochenbericht. [Current weekly report – GrippeWeb weekly report]. Berlin: RKI. [Accessed 24 Jan 2025]. Available from: https://www.rki.de/DE/Content/Infekt/Sentinel/Grippeweb/Wochenberichte/Wochenbericht_aktuell.html
  2. RespiVirNet – Sorveglianza integrata dei virus respiratori. Rapporto influnet. [Integrated Surveillance of Respiratory Viruses. Influenza Report]. Rome: Istituto Superiore di Sanità. [Accessed 24 Jan 2025]. Available from: https://respivirnet.iss.it/pagine/rapportoInflunet.aspx
  3. Santé publique France (SPF). Infections respiratoires aiguës (grippe, bronchiolite, COVID-19). [Acute respiratory infections (influenza, bronchiolitis, COVID-19)]. Bulletin du 8 janvier 2025. Saint Maurice: SPF. [Accessed 21 Jan 2025]. Available from: https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/grippe/documents/bulletin-national/infections-respiratoires-aigues-grippe-bronchiolite-covid-19-.-bulletin-du-8-janvier-2025
  4. UK Health Security Agency (UKHSA). Influenza | UKHSA data dashboard. London: UKHSA. [Accessed 24 Jan 2025]. Available from: https://ukhsa-dashboard.data.gov.uk/respiratory-viruses/influenza
  5. European Respiratory Virus Surveillance Summary (ERVISS). [Accessed 24 Jan 2025]. Available from: https://erviss.org/
  6. Traore A, Charniga K, Grellet S, Terpant G, Da Cruz H, Lamy A, et al. , RELAB Study Group, Laboratory group, Members of the Laboratory Group, Members of the RELAB Study Group. Monitoring SARS-CoV-2 variants with complementary surveillance systems: risk evaluation of the Omicron JN.1 variant in France, August 2023 to January 2024. Euro Surveill. 2025;30(1):2400293.  https://doi.org/10.2807/1560-7917.ES.2025.30.1.2400293  PMID: 39790077 
  7. World Health Organization (WHO). Recommendations announced for influenza vaccine composition for the 2024-2025 northern hemisphere influenza season. Geneva: WHO; 23 February 2024. Available from: https://www.who.int/news/item/23-02-2024-recommendations-announced-for-influenza-vaccine-composition-for-the-2024-2025-northern-hemisphere-influenza-season
  8. Blanquart F, Abad C, Ambroise J, Bernard M, Débarre F, Giannoli J-M, et al. Temporal, age, and geographical variation in vaccine efficacy against infection by the Delta and Omicron variants in the community in France, December 2021 to March 2022. Int J Infect Dis. 2023;133:89-96.  https://doi.org/10.1016/j.ijid.2023.04.410  PMID: 37182550 
  9. Chung JR, Price AM, Zimmerman RK, Moehling Geffel K, House SL, Curley T, et al. , US Flu VE Network Investigators. Influenza vaccine effectiveness against medically attended outpatient illness, United States, 2023-24 season. Clin Infect Dis. 2025;ciae658.  https://doi.org/10.1093/cid/ciae658  PMID: 39761230 
  10. Kissling E, Maurel M, Emborg H-D, Whitaker H, McMenamin J. Howard J, et al. Interim 2022/23 influenza vaccine effectiveness: six European studies, October 2022 to January 2023. Euro Surveill. 2023;28(21):2300116. .
  11. Maurel M, Howard J, Kissling E, Pozo F, Pérez-Gimeno G, Buda S, et al. , European IVE group. Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024. Euro Surveill. 2024;29(8):2400089.  https://doi.org/10.2807/1560-7917.ES.2024.29.8.2400089  PMID: 38390651 
  12. Abou Chakra CN, Blanquart F, Vieillefond V, Enouf V, Visseaux B, Haim-Boukobza S, et al. Vaccine Effectiveness Dynamics against Influenza and SARS-CoV-2 in Community-tested Patients in France 2023-2024. Emerg Microbes Infect. [Accepted 7 Feb 2025]. Forthcoming.
  13. Smith DJ, Lapedes AS, de Jong JC, Bestebroer TM, Rimmelzwaan GF, Osterhaus ADME, et al. Mapping the antigenic and genetic evolution of influenza virus. Science. 2004;305(5682):371-6.  https://doi.org/10.1126/science.1097211  PMID: 15218094 
  14. Separovic L, Zhan Y, Kaweski SE, Sabaiduc S, Carazo S, Olsha R, et al. Interim estimates of vaccine effectiveness against influenza A(H1N1)pdm09 and A(H3N2) during a delayed influenza season, Canada, 2024/25. Euro Surveill. 2025;30(4):2500059.  https://doi.org/10.2807/1560-7917.ES.2025.30.4.2500059  PMID: 39885824 
  15. DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371(7):635-45.  https://doi.org/10.1056/NEJMoa1315727  PMID: 25119609 
  16. Tsang TK, Gostic KM, Chen S, Wang Y, Arevalo P, Lau EHY, et al. Investigation of the Impact of Childhood Immune Imprinting on Birth Year-Specific Risk of Clinical Infection During Influenza A Virus Epidemics in Hong Kong. J Infect Dis. 2023;228(2):169-72.  https://doi.org/10.1093/infdis/jiad009  PMID: 36637115 
  17. Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet. 2005;366(9492):1165-74.  https://doi.org/10.1016/S0140-6736(05)67339-4  PMID: 16198765 
  18. Lipsitch M, Jha A, Simonsen L. Observational studies and the difficult quest for causality: lessons from vaccine effectiveness and impact studies. Int J Epidemiol. 2016;45(6):2060-74.  https://doi.org/10.1093/ije/dyw124  PMID: 27453361 
  19. Hernán MA, Monge S. Selection bias due to conditioning on a collider. BMJ. 2023;381:1135.  https://doi.org/10.1136/bmj.p1135  PMID: 37286200 
  20. Schnitzer ME, Ortiz-Brizuela E, Carabali M, Talbot D. Bias-interpretability Trade-offs in Vaccine Effectiveness Studies Using Test-negative or Cohort Designs. Epidemiology. 2024;35(2):150-3.  https://doi.org/10.1097/EDE.0000000000001708  PMID: 38290138 
  21. Santé publique France (SPF). Infections respiratoires aiguës (grippe, bronchiolite, COVID-19). [Acute respiratory infections (influenza, bronchiolitis, COVID-19)]. Bulletin du 29 janvier 2025. Saint Maurice: SPF. [Accessed 4 Feb 2025]. Available from: https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/grippe/documents/bulletin-national/infections-respiratoires-aigues-grippe-bronchiolite-covid-19-.-bulletin-du-29-janvier-2025
  22. Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol. 2006;35(2):337-44.  https://doi.org/10.1093/ije/dyi274  PMID: 16368725 
  23. Remschmidt C, Wichmann O, Harder T. Frequency and impact of confounding by indication and healthy vaccinee bias in observational studies assessing influenza vaccine effectiveness: a systematic review. BMC Infect Dis. 2015;15(1):429.  https://doi.org/10.1186/s12879-015-1154-y  PMID: 26474974 
Influenza vaccine effectiveness against detected infection in the community, France, October 2024 to February 2025
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Fran%C3%A7ois+Blanquart&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Blanquart François</a>, <a href="/search?value1=Vincent+Vieillefond&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Vieillefond Vincent</a>, <a href="/search?value1=Benoit+Visseaux&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Visseaux Benoit</a>, <a href="/search?value1=Claire+Nour+Abou+Chakra&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Abou Chakra Claire Nour</a>, <a href="/search?value1=Marta+C+Nunes&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Nunes Marta C</a>, <a href="/search?value1=Alexandra+Jacques&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Jacques Alexandra</a>, <a href="/search?value1=Stephanie+Haim-Boukobza&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Haim-Boukobza Stephanie</a>, <a href="/search?value1=Laurence+Josset&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Josset Laurence</a>, <a href="/search?value1=Valentin+Wehrle&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Wehrle Valentin</a>, <a href="/search?value1=Guillaume+Deleglise&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Deleglise Guillaume</a>, <a href="/search?value1=Thomas+Duret&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Duret Thomas</a>, <a href="/search?value1=Marie+Anne+Rameix-Welti&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Rameix-Welti Marie Anne</a>, <a href="/search?value1=Bruno+Lina&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Lina Bruno</a>, <a href="/search?value1=Vincent+Enouf&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Enouf Vincent</a>, <a href="/search?value1=on+behalf+of+the+RELAB+study+group&option1=author&noRedirect=true" class="nonDisambigAuthorLink">on behalf of the RELAB study group</a>, <a href="/search?value1=Antonin+Bal&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bal Antonin</a></span>. Influenza vaccine effectiveness against detected infection in the community, France, October 2024 to February 2025. <a href="/content/ecdc">Euro Surveill.</a> 2025;30(7):pii=2500074. <a href="https://doi.org/10.2807/1560-7917.ES.2025.30.7.2500074" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2025.30.7.2500074</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 24 Jan 2025;&nbsp;&nbsp; <span class="generated">Accepted</span>: 20 Feb 2025 </span> </p>
/content/10.2807/1560-7917.ES.2025.30.7.2500074
/content/10.2807/1560-7917.ES.2025.30.7.2500074
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error